Holder snapshot 7 signals
Share change
-27,345,949
Put/Call ratio
48%
SEC-reported price per share
$0.54
Indexed holders
79
Value change
-$30,501,887
Number of buys
27
Open additional details 1 more signal available
Number of sells
35
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
1,571,428,571

Security key

00653A107

Report period

Q4 2024

Indexed institutions

79

Top holders

10

Ownership snapshot

Top reported holders of ADAPY - Adaptimmune Therapeutics PLC - American Depositary Shares, each representing 6 Ordinary Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BAILLIE GIFFORD & CO
Disclosed value leader
Matrix Capital Management...
Comparable rows
1/15
Latest evidence
31 Dec 2024
13D/G 13F Lead comparable stake: 4.6% 14 rows are not safely comparable across share classes. 13D/G row: BAILLIE GIFFORD & CO Showing 1-6 of 15 holder rows.

Quick read

BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 4.6%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BAILLIE GIFFORD & CO's linked filing trail.
Comparable ownership Top 1
BAILLIE GIFFORD & CO 4.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BAILLIE GIFFORD & CO
13D/G 13F
Company
4.6%
Reported 13D/G · 31 Dec 2024
$19,146,934
70,914,570 shares
$0 31 Dec 2024
Matrix Capital Management Company, LP
13F
Company
13F
—
denominator unverified
$35,812,512
37,681,515 shares
— 30 Sep 2024
EcoR1 Capital, LLC
13F
Company
13F
—
denominator unverified
$26,044,828
27,404,070 shares
— 30 Sep 2024
NEA Management Company, LLC
13F
Company
13F
—
denominator unverified
$16,225,789
17,079,778 shares
— 30 Sep 2024
Long Focus Capital Management, LLC
13F
Company
13F
—
denominator unverified
$12,640,215
13,299,890 shares
— 30 Sep 2024
PFM Health Sciences, LP
13F
Company
13F
—
denominator unverified
$9,504,748
10,000,787 shares
— 30 Sep 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
79
Shares
124,428,941
Indexed holders
79
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q4 2024 vs Q3 2024 Across Filers

Q3 2024 indexed holders
79
Q4 2024 indexed holders
79
Indexed holder difference
0
Investor Q3 2024 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2024 value Q4 2024 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .